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Objectives: Evidence on contraceptive self-injection from the United States and similar settings is promising, and the practice may increase
access. There are no published studies on the feasibility of contraceptive self-injection in sub-Saharan Africa to date. The purpose of this
study was to assess feasibility of subcutaneous depot medroxyprogesterone acetate self-injection in Uganda, with specific objectives to (a)
measure the proportion of participants who self-injected competently, (b) measure the proportion who self-injected on time 3 months after
training (defined conservatively as within 7 days of their reinjection date) and (c) assess acceptability.
Study design: In this prospective cohort study, 380 18–45-year-old participants completed self-injection training by licensed study nurses,
guided by a client instruction booklet, and practiced injection on prosthetics until achieving competence. Nurses supervised participants' self-
injection and evaluated injection technique using an observation checklist. Those judged competent were given a Sayana® Press unit,
instruction booklet and reinjection calendar for self-injection at home 3 months later. Participants completed an interview before and after
self-injection. Nurses visited participants at home following reinjection dates; during the follow-up visit, participants demonstrated self-
injection on a prosthetic, injection technique was reevaluated, and a postreinjection interview was completed.
Results: Of 368 participants followed up 3 months posttraining, 88% [95% confidence interval (CI) = 84–91] demonstrated injection
competence, and 95% (95% CI=92–97) reinjected on time, while 87% (95% CI=84–90) were both on time and competent. Nearly all (98%)
expressed a desire to continue.
Conclusions: Self-injection is feasible and highly acceptable among most study participants in Uganda.
Implications: The first research results on contraceptive self-injection in sub-Saharan Africa indicate initial feasibility and acceptability of
the practice 3 months after women received one-on-one training and a highly visual training and memory aid. Results can inform self-
injection programs which aim to increase women's autonomy and access to injectable contraception.
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Injectable contraceptives are the most popular modern
method in Uganda, representing about 56% of contraceptive
use for married women [1]. However, about 25% of all
women in Uganda still have an unmet need for modern
contraception [1]. Expanding service-delivery options
through self-injection may improve injectable access partic-
ularly in remote areas — eliminating the need to returnicle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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health worker — and may offer enhanced confidentiality to
women whose partners or social network oppose contracep-
tive use (although it could also be challenging for these
women to store devices and inject at home).
Depo-subQ Provera 104 is a variation of intramuscular
depot medroxyprogesterone acetate (DMPA-IM) that con-
tains 104 rather than 150 mg of DMPA administered as a
subcutaneous injection (DMPA-SC). DMPA is effective and
safe in either form. A recent review of 14 studies concluded
that DMPA-SC and DMPA-IM are therapeutically equiva-
lent, with similar side effects profiles [2]. Aggregated data
from seven clinical trials of DMPA-IM and two trials of
DMPA-SC revealed a first-year failure rate of 2 per 1000
women [3].
Sayana® Pressi (DMPA-SC in the Uniject™ injection
systemii) received regulatory approval in Europe in 2012 and
Uganda in 2014. The Uniject™ is a small, prefilled,
autodisable device that requires minimal training for use.
Acceptability studies of Sayana® Press found that most
injectable clients and providers in Uganda and Senegal
preferred Sayana® Press over DMPA-IM [4–6]. In 2015, the
UK Medicines and Healthcare products Regulatory Agency
approved relabeling Sayana® Press to support self-injection
[7]. As of mid-2016, a similar update is under review by the
Uganda National Drug Authority and in a few other
countries as well.
Although self-injection of contraceptives is relatively
new, a limited number of studies have been conducted.
Pfizer Inc. tested the safety and efficacy of self-injection of
DMPA-SC in a prefilled syringe involving 6279
women-cycles of exposure via self-injection [8]. Women
reported self-injection was convenient and easy. There were
no pregnancies among women practicing self-injection in
these original clinical trials or studies in Florida [9], Scotland
[10] and New York [11], although it is important to note that
these studies involved limited women-months of exposure
due to small samples and short time frames. Self-injection of
another injectable contraceptive delivered in a prefilled
Uniject™ device, Cyclofem®, was also tested at health
clinics in Brazil nearly 20 years ago; 90% of women who
self-injected did so correctly, although nearly half of the
women invited to do so opted not to self-inject [12]. To date,
there have been no published studies on the feasibility of
contraceptive self-injection in sub-Saharan Africa.
The purpose of our study was to assess feasibility and
acceptability of self-injection with DMPA-SC in Uniject™
in Uganda. The two primary objectives were to measure the
proportion of study participants who demonstrate competent
self-injection technique 3 months after training and to
measure the proportion who self-inject on time. Our
secondary objective was to assess the acceptability of
self-injection reflected in the proportions who expressed ai Sayana® Press is a registered trademark of Pfizer Inc.
ii Uniject™ is a trademark of BD.desire to continue with self-injection and who reported that
they were likely or very likely to recommend the practice to
others.2. Material and methods
2.1. Study design and procedures
This prospective cohort study was conducted in three
public facilities in Mubende District and one NGO clinic and
two public facilities in Gulu District of Uganda from June to
December 2015. These sites included two rural facilities, two
urban hospitals, an urban facility that serves youth and does
outreach to rural areas and a periurban facility located near a
college. Female participants were 18 to 45 years of age and
eligible to receive injectable contraception per standard of
care guidelines. All had sought care at the clinic and decided
to use injectable contraception prior to recruitment, and all
provided signed informed consent. Anyone who was
pregnant, did not reside permanently in the area, felt unwell
on the day of enrollment or did not speak the primary
language of the area was excluded from the study. The study
received institutional review board (IRB) approval from the
PATH Research Ethics Committee and the Mulago Hospital
IRB in Uganda.
Study procedures were implemented by licensed nurses
who had been trained in Sayana® Press administration,
research ethics (including Good Clinical Practice), inter-
viewing, and how to train and counsel women for
self-injection.
Study participants were trained one-on-one by study
nurses guided by a client instruction booklet (Appendix A)
[13] as a visual aid and practiced the injection on a prosthetic
device until competence was achieved (study definition of
competence is provided in Section 2.2). Client instruction
booklets were designed for low-literacy audiences and
pretested in Uganda to maximize usability. Training
included calculation of injection dates, review of DMPA
side effects and protection against HIV, safe home storage
and appropriate disposal practices (e.g., placing the used
device in an impermeable container before disposing of it in
the latrine, retaining the container).
At enrollment and after training, women self-injected
under the supervision of a nurse. Their injection technique
was evaluated using an observation checklist (Appendix B)
[14]. Participants completed two structured interviews on the
day of enrollment: one baseline interview before and one
postinjection interview. Those judged to be competent,
consistent with the checklist, were given one Sayana® Press
unit, the client instruction booklet and a reinjection calendar
with the reinjection date marked. Three months after the
observed self-injection, participants were instructed to
self-inject independently at home.
At follow-up, each self-injecting participant was visited at
home by the study nurse at least 7 days following her
scheduled reinjection date so that it was feasible to assess
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participant demonstrated the injection steps on a prosthetic
device without guidance from the study nurse, and her
technique was evaluated according to the observation
checklist. If she had forgotten to do the injection, the nurse
observed and evaluated as she gave herself the injection. If
she did not want to self-inject but wished to continue with the
method, the nurse administered the injection. Every woman
completed a follow-up interview, regardless of whether she
self-injected.
2.2. Data collection and analysis
Data were collected via structured questionnaires in private
face-to-face interviews with each study participant. Interviews
were conducted in the local language (or English, if preferred
by participants) by female interviewers, and data were entered
electronically on Android tablets. The same study nurses who
enrolled women conducted the follow-up visits.
A sample size of 380 self-injectors was calculated to
achieve a desired precision of 5 percentage points around the
point estimate of 80% of women competent in self-injection
at 3 months [95% confidence interval (CI)=75%–85%] and a
precision of 5 percentage points around the point estimate of
80% of women reinjecting consistent with the schedule. TheTable 1
Baseline characteristics of participants
Percent or mean n/N
Mean age in years 26.0 (SD=6.0) 380
Education 380
None 8.7 33
Primary 56.8 216
Secondary 29.7 113
Postsecondary 4.7 18
Marital status 380
Married and cohabiting 67.6 257
Married, living apart 13.7 52
Single 18.7 71
Mean parity 2.9 (SD=1.9) 380
Contraceptive experience 380
New user of family planning 10.5 40
New user of the injectable 10.3 39
Experienced injectable user 79.2 301
Partner supports family planning use 71.2 269/378
Concerned about privacy at the clinic 379
Not at all concerned 83.9 318
A little concerned 12.9 49
Very concerned 3.2 12
Level of anxiety about self-injection 0.32 (SD=0.51) 377
Number of practice attempts prior to
self-injection
2.7 (SD=0.91) 380
Travel time to reach clinic 380
b30 min 54.0 205
30 min–1 h 27.6 105
1–2 h 12.1 46
N2 h 5.1 24
Paid for transport to reach clinic 44.6 169/379
Mean travel expense (in $) if N0 $0.87 (SD = $0.72) 169
Missed work for clinic visit 34.9 132/378sample size assumed 10% lost to follow-up and 20%
discontinuation of the injectable.
The primary objective of evaluating competency in
self-injection had two end points: the percent of women
who demonstrated correct self-injection technique consistent
with the observation checklist and the percent who reinjected
on schedule, i.e., within 1 week of their reinjection date. To
qualify as competent, a participant had to successfully
demonstrate 5 critical injection steps from the 19-step
observation checklist (Appendix B) [14]. The five critical
steps were so designated since the omission of any of these
steps could lead to an ineffective injection. The five steps are
as follows: (a) select an appropriate injection site, (b) mix the
solution by shaking vigorously, (c) push the needle shield and
port together to activate the device, (d) pinch the skin to form
a “tent” and (e) squeeze the reservoir slowly to inject the
contraceptive. Women who did not demonstrate competence
at the first injection were not given Sayana® Press for
independent self-injection at home and were exited from the
study. Women who discontinued the injectable (e.g., switched
methods or stopped family planning in order to become
pregnant) and women lost to follow-up were not included in
the denominator for the calculation of the primary outcomes.
Data analysis was performed using STATA version 14.1.
95% CIs for the primary end points were calculated using
exact CIs for binomial proportions.3. Results
3.1. Participant characteristics
A total of 384 participants enrolled in the study. Two
women enrolled were later determined ineligible due to
pregnancy (both screening failures at the time of recruit-
ment). Data were lost for one enrolled participant, and one
participant did not complete enrollment study procedures.
For baseline data analysis purposes, participants consisted of
380 healthy female adults who agreed to use injectable
contraception and were willing to try self-injection. Table 1
summarizes the sample characteristics.
3.2. Injection competence and adherence to
reinjection schedule
Among the 380 self-injectors, 98% demonstrated com-
petence immediately after training. Seven women were lost
to follow-up, and five women discontinued the injectable for
reasons unrelated to self-injection — leaving 368 partici-
pants for follow-up analysis. Among these participants, 88%
demonstrated competence immediately and 3 months later
(Table 2).iii Among the 360 women who reinjected at 3iii The eight women who did not qualify as competent for the first
injection did not continue with the study but are included in the
denominator for the calculation of percent competent (the primary
outcome). Note that since they were not permitted to continue with
independent self-injection, these eight cases are not included in the
calculation for the percent reinjecting on schedule.
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women injected between 2 and 4 weeks early, and 14
women injected 2 to 3 weeks late (Table 2). A total of 87% of
women who reinjected were both competent and on time.
Note that five women demonstrated the injection on
themselves rather than a prosthetic since they had not yet
self-injected at the time of the follow-up visit.
With respect to subjective competency, 92% reported that
their second injection was “very easy” to do (Fig. 1), an
increase from 61% for the first injection. Four out of five
(79%) were “very confident” that they gave the second
injection correctly, an increase from 68% (Fig. 2). The vast
majority of women (96%) reported using the client
instruction booklet as a guide for their independent
self-injection (data not shown).
3.3. Acceptability of self-injection
Nearly all of those who gave two injections (98%)
expressed a desire to continue with self-injection (data not
shown), and 88% reported they were “very likely” to
recommend the practice to others (Fig. 3).
3.4. Safety
There were no serious adverse events. The most common
adverse events were known side effects of DMPA:
amenorrhea and other changes in menstrual bleeding
patterns, including spotting. Twenty-two women experi-
enced an injection-site reaction (ISR) in the form of a dimple,
bruise, blister or nodule, and three women sought treatment
or advice for an ISR. All adverse events were mild to
moderate in severity.
3.5. Storage and disposal
Nearly all women (98%) felt that they were able to keep
the device secure (safe from discovery by children or others)
until it was time for reinjection, with most (61%) storing it inTable 2
Injection competence and adherence to reinjection schedule
% 95% CI n/N
Women demonstrating competence
immediately posttraining
97.9 95.9–99.1 372/380
Women demonstrating competence
3 months posttraining
88.0 84.3–91.2 324/368
Women who reinjected on
schedule (±1 week)
95.0 92.2–97.0 342/360
Reinjection timing: 360
4 weeks early (22–30 days early) 0.6 2
3 weeks early (15–21 days early) 0.3 1
2 weeks early (7–14 days early) 0.3 1
On time (±1 week) 95.0 342
2 weeks late (7–14 days late) 3.3 12
3 weeks late (15–21 days late) 0.6 2
Percent of women reinjecting on
schedule and demonstrating
competence at follow-up
86.9 83.0–90.2 313/360a handbag (Table 3). Discarding the device in a pit latrine
was the preferred disposal strategy (94%), although some
returned the device to the clinic or kept it for the study nurse,
and two women discarded it with the household garbage.
About 7 in 10 women (71%) stored the spent device in an
impermeable household container (as instructed during
training) until it could be safely discarded.4. Discussion
This study provides the first evidence from sub-Saharan
Africa that self-injection of DMPA-SC in Uniject™ is
feasible for the vast majority of women after a single
one-on-one training session — including women with
limited education and younger women. These results echo
previous studies on self-injection from developed countries
but further demonstrate that self-injection is feasible and
desirable in settings where women have relatively less
education and access to health information and services.
The results of this study also point to important program
and policy implications for potential introduction of
injectable contraceptive self-injection [15,16], which could
help increase women's contraceptive access and autonomy.
The Sayana® Press manufacturer has announced the
intention to register self-injection in an increasing number
of countries over the next 1 or 2 years [7], and additional
studies of feasibility and impact of the practice are planned or
ongoing in Ghana, Democratic Republic of Congo, Nigeria,
Uganda, Senegal and Malawi. If and when national drug
authorities officially approve self-injection, ministries of
health and family planning implementing organizations will
need to make evidence-informed decisions about integration
of self-injection into routine family planning service
delivery.
Our results provide additional context following the
recent recommendation of the World Health Organization
that self-injection be offered “in contexts where mechanisms
to provide the woman with appropriate information and
training exist, referral linkages to a healthcare provider are
strong, and where monitoring and follow-up can be ensured”
[17]. Self-injection competence in this study was achieved
for most women in the context of one-on-one training that
included review of a booklet geared toward low-literacy
audiences and as many practice injections as needed. The
time required for training and support of clients in this
research study was considerable, and given the many duties
of family planning providers, this may be difficult to
replicate in daily practice. The provision of supplies to
support the training, including saline-filled Uniject™
devices for practice injections, models for injection practice
(salt-filled condoms), instruction booklets and calendars,
complicates and increases the costs of offering self-injection.
A next step for the field will be to design simpler, low-cost
but still evidence-based approaches to self-injection practice
to rigorously monitor/evaluate actual practice, including the
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Fig. 1. Reported ease of self-injection.
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Fig. 3. Likelihood of recommending self-injection.
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important to recognize that time and other costs invested in
training clients up front may be offset over the long run by
reduced clinic visits for women who continue injecting at
home.
Disposal of used devices is another unresolved challenge.
Latrine disposal removes the spent device from risk of
contact quickly but may not be an ideal strategy given
limited global access to sanitation facilities [18] and
questionable appropriateness of disposal of medical devices
in latrines. Programs should strategize ways to recapture
spent devices for incineration without defeating the purpose
of self-injection by requiring women to return the device to
the clinic. Our results suggest that extra focus during training
is needed to encourage more women to secure the device in a
locally available, impermeable container prior to elimination
[19].
4.1. Study limitations
By design, self-injection was not directly observed at the
3-month reinjection time, and it is possible that injections
demonstrated on the model may not mirror women's actual
practices. Moreover, the five women who self-injected at
follow-up rather than injecting on a prosthetic reflect a
difference in instrumentation of unknown significance. The
small number of cases that differ in this regard is unlikely to68.2
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Fig. 2. Confidence in ability to self-inject.influence the results. Because of the timing of the follow-up
visit (within the 4-week reinjection window for DMPA) [20],
we could not assess whether women would have remem-
bered to self-inject within the window if not for the study
nurse follow-up visit. The rationale for conducting follow-up
within the window was to ensure that women who had not
yet done the injection could receive the injection from the
study nurse if desired. The study involved only one
unsupervised self-injection; women's recall of injection
technique or timing might decrease or increase over time,
and their need for support from providers may or may not
increase with time/more injections.
An additional limitation is that we did not vary our
approach to training clients to self-inject, so it is not possible
to assess which specific components of our approach were
critical to competent and on-time client reinjection or
acceptability — in other words, whether one-on-one
training, practice injections or client instruction booklets
were critical to our outcomes.
Participants were recruited at public-sector family
planning clinics from among clients who had selected
injectable contraception. Had there been awareness raising
regarding the opportunity to try self-injection, a different
family planning clientele and possibly more new users may
have been attracted. Feasibility and/or acceptability might
vary for clients who typically receive contraceptives from
community health workers.Table 3
Storage and disposal
% n/N
Device kept secure until use 97.5 355/366
Storage location 364
Handbag 61.3 223
Suitcase 21.2 77
Other 17.6 57
Spent device disposal 354
Returned to clinic 3.39 12
Kept for study nurse 2.26 8
Put in household garbage 0.56 2
Dumped in pit latrine 93.79 332
Stored in container until disposal 71.5 253/354
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